NEW YORK (GenomeWeb News) — The US Food and Drug Administration is creating a consortium with members of the pharmaceutical industry and academia that aims to observe how genetic biomarkers contribute to serious adverse events, according to an NIH report and people familiar with the project.
 
The FDA’s decision to form the initiative, called the Serious Adverse Events Consortium, comes at a time when a chorus of critics increasingly blames the agency for not doing enough to ensure the safety of marketed drugs.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.